New dissolving trimedat tablet tested for digestive disorders

NCT ID NCT07421011

Recruiting now Knowledge-focused Sponsor: Valenta Pharm JSC Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares a new orally disintegrating form of Trimedat (trimebutine) to the standard tablet in 36 healthy adults. The goal is to see if the new version is absorbed similarly and is safe. This trial does not treat any disease; it only gathers data on how the drug behaves in the body.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Trimebutine Maleate (Trimedat)
What this could lead to: If successful, this could provide a more convenient tablet form for people with digestive issues like IBS or GERD.
What could go wrong: This is an early-stage trial in only 36 healthy people, not patients. It only checks how the drug is processed, not if it works for any condition.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BILIARY DYSKINESIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

biliary dyskinesia cholelithiasis gastroesophageal reflux disease irritable bowel syndrome postcholecystectomy syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BILIARY DYSKINESIA GALLSTONE DISEASE GERD IRRITABLE BOWEL SYNDROME POSTCHOLECYSTECTOMY SYNDROME

Contacts and locations

Locations

Federal Budgetary Institution of Science "North-West Public Health Research Center"
RECRUITING

Saint Petersburg, 191036, Russia

More trials for these conditions

Other studies related to the condition(s) this trial covers.